Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin and erdosteine for primary ciliary dyskinesia
ACTRN12619000564156Phase 4Completed
- Sponsor
- Menzies School of Health Research
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of azithromycin and erdosteine in primary ciliary dyskinesia (PCD) (4 arms), sponsored by Menzies School of Health Research. Primary endpoint: Respiratory exacerbation rate. Started Aug 2020; status: completed.
02
Drugs
azithromycinerdosteine
03
Conditions
primary ciliary dyskinesia (PCD)
Beyond the preview
Go deeper on ACTRN12619000564156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000564156.